DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

Proton Radiotherapy for Extremity Soft Tissue Sarcoma

Phase 2

Terminated

Conditions: Soft Tissue Sarcoma of the Extremities

Interventions: Radiation: Proton Therapy

First Posted Date: 2012-03-23

Last Posted Date: 2019-12-06

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 1

Registration Number: NCT01561495

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Proton Radiotherapy for Stage I, IIA, and IIB Seminoma

Not Applicable

Completed

Conditions: Stage I, IIA and IIB Seminoma

Interventions: Radiation: Proton Radiation Therapy

First Posted Date: 2012-03-20

Last Posted Date: 2020-04-13

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 5

Registration Number: NCT01557790

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Massachusettes General Hospital, Boston, Massachusetts, United States

Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy

Phase 1

Completed

Conditions: Prostate Cancer Patients With Detectable PSA Following Prostatectomy

First Posted Date: 2012-03-08

Last Posted Date: 2018-08-22

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 19

Registration Number: NCT01548807

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Does Cryofixation of Skin Specimens Affect Quality of Subsequent Formalin Fixed Paraffin Embedded H and E Histology

Completed

Conditions: Squamous Cell Carcinoma
Basal Cell Carcinoma

First Posted Date: 2012-02-29

Last Posted Date: 2019-07-31

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 180

Registration Number: NCT01540695

Locations: 🇺🇸
Abramsonc Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

MLN8237 in Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2012-02-29

Last Posted Date: 2018-08-29

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 9

Registration Number: NCT01540682

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer

Phase 1

Completed

Conditions: Urothelial Carcinoma of the Bladder

First Posted Date: 2012-01-27

Last Posted Date: 2019-11-26

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 2

Registration Number: NCT01520038

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma

Phase 1

Completed

Conditions: Metastatic Clear Cell Renal Cell Carcinoma

Interventions: Drug: Hydroxychloroquine
Drug: RAD001

First Posted Date: 2012-01-13

Last Posted Date: 2020-04-24

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 40

Registration Number: NCT01510119

Locations: 🇺🇸
University of Pittsburgh, Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer

Phase 1

Completed

Conditions: Metastatic Adenocarcinoma
Advanced Adenocarcinoma

Interventions: Drug: Hydroxychloroquine (HCQ)
Drug: Abraxane
Drug: Gemcitabine

First Posted Date: 2012-01-10

Last Posted Date: 2022-03-31

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 119

Registration Number: NCT01506973

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA

Phase 1

Completed

Conditions: Metastatic Melanoma

Interventions: Drug: Ipilimumab
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2011-12-23

Last Posted Date: 2021-08-10

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 22

Registration Number: NCT01497808

Locations: 🇺🇸
Abramson Cancer Center of the Universirty of Pennsylvania, Philadelphia, Pennsylvania, United States

A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia

Phase 1

Terminated

Conditions: Acute Myelogenous Leukemia

Interventions: Drug: Birinapant

First Posted Date: 2011-12-07

Last Posted Date: 2021-06-24

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 27

Registration Number: NCT01486784

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy